Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Changes in glucose-induced plasma active glucagon-like peptide-1 levels by co-administration of sodium-glucose cotransporter inhibitors with dipeptidyl peptidase-4 inhibitors in rodents.

Oguma T, Kuriyama C, Nakayama K, Matsushita Y, Hikida K, Tsuda-Tsukimoto M, Saito A, Arakawa K, Ueta K, Minami M, Shiotani M.

J Pharmacol Sci. 2016 Dec;132(4):255-261. doi: 10.1016/j.jphs.2016.10.006. Epub 2016 Oct 28.

2.

Intestinal Sodium Glucose Cotransporter 1 Inhibition Enhances Glucagon-Like Peptide-1 Secretion in Normal and Diabetic Rodents.

Oguma T, Nakayama K, Kuriyama C, Matsushita Y, Yoshida K, Hikida K, Obokata N, Tsuda-Tsukimoto M, Saito A, Arakawa K, Ueta K, Shiotani M.

J Pharmacol Exp Ther. 2015 Sep;354(3):279-89. doi: 10.1124/jpet.115.225508. Epub 2015 Jun 23.

PMID:
26105952
3.

Novel Indole-N-glucoside, TA-1887 As a Sodium Glucose Cotransporter 2 Inhibitor for Treatment of Type 2 Diabetes.

Nomura S, Yamamoto Y, Matsumura Y, Ohba K, Sakamaki S, Kimata H, Nakayama K, Kuriyama C, Matsushita Y, Ueta K, Tsuda-Tsukimoto M.

ACS Med Chem Lett. 2013 Nov 13;5(1):51-5. doi: 10.1021/ml400339b. eCollection 2014 Jan 9.

4.

N-Glucosides as human sodium-dependent glucose cotransporter 2 (hSGLT2) inhibitors.

Yamamoto Y, Kawanishi E, Koga Y, Sakamaki S, Sakamoto T, Ueta K, Matsushita Y, Kuriyama C, Tsuda-Tsukimoto M, Nomura S.

Bioorg Med Chem Lett. 2013 Oct 15;23(20):5641-5. doi: 10.1016/j.bmcl.2013.08.042. Epub 2013 Aug 17.

PMID:
23999047
5.

C-Glucosides with heteroaryl thiophene as novel sodium-dependent glucose cotransporter 2 inhibitors.

Koga Y, Sakamaki S, Hongu M, Kawanishi E, Sakamoto T, Yamamoto Y, Kimata H, Nakayama K, Kuriyama C, Matsushita Y, Ueta K, Tsuda-Tsukimoto M, Nomura S.

Bioorg Med Chem. 2013 Sep 1;21(17):5561-72. doi: 10.1016/j.bmc.2013.05.048. Epub 2013 Jun 4.

PMID:
23809172
6.

Impact of intestinal glucuronidation on the pharmacokinetics of raloxifene.

Kosaka K, Sakai N, Endo Y, Fukuhara Y, Tsuda-Tsukimoto M, Ohtsuka T, Kino I, Tanimoto T, Takeba N, Takahashi M, Kume T.

Drug Metab Dispos. 2011 Sep;39(9):1495-502. doi: 10.1124/dmd.111.040030. Epub 2011 Jun 6.

PMID:
21646435
7.

Discovery of canagliflozin, a novel C-glucoside with thiophene ring, as sodium-dependent glucose cotransporter 2 inhibitor for the treatment of type 2 diabetes mellitus.

Nomura S, Sakamaki S, Hongu M, Kawanishi E, Koga Y, Sakamoto T, Yamamoto Y, Ueta K, Kimata H, Nakayama K, Tsuda-Tsukimoto M.

J Med Chem. 2010 Sep 9;53(17):6355-60. doi: 10.1021/jm100332n.

PMID:
20690635
8.

Cocktail-substrate assay system for mechanism-based inhibition of CYP2C9, CYP2D6, and CYP3A using human liver microsomes at an early stage of drug development.

Mori K, Hashimoto H, Takatsu H, Tsuda-Tsukimoto M, Kume T.

Xenobiotica. 2009 Jun;39(6):415-22. doi: 10.1080/00498250902822204.

PMID:
19480547
9.

Effect of plasma protein binding on in vitro-in vivo correlation of biliary excretion of drugs evaluated by sandwich-cultured rat hepatocytes.

Fukuda H, Ohashi R, Tsuda-Tsukimoto M, Tamai I.

Drug Metab Dispos. 2008 Jul;36(7):1275-82. doi: 10.1124/dmd.107.019026. Epub 2008 Apr 3.

PMID:
18388177
10.

Characterization of hepatobiliary transport systems of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035.

Tsuda-Tsukimoto M, Maeda T, Iwanaga T, Kume T, Tamai I.

Pharm Res. 2006 Nov;23(11):2646-56. Epub 2006 Sep 13.

PMID:
16969695
11.
12.

Role of human liver cytochrome P450 2C9 in the metabolism of a novel alpha4beta1/alpha4beta7 dual antagonist, TR-14035.

Tsuda-Tsukimoto M, Ogasawara Y, Kume T.

Drug Metab Pharmacokinet. 2005 Apr;20(2):127-34.

Supplemental Content

Loading ...
Support Center